-
Something wrong with this record ?
Do AMPA/kainate antagonists possess potential in the treatment of addiction? Evidence from animal behavioural studies
M. Hrickova, J. Ruda-Kucerova
Language English Country England, Great Britain
Document type Journal Article, Review
- MeSH
- Receptors, AMPA * antagonists & inhibitors MeSH
- Excitatory Amino Acid Antagonists * therapeutic use pharmacology MeSH
- Behavior, Animal * drug effects MeSH
- Humans MeSH
- Behavior, Addictive * drug therapy MeSH
- Substance-Related Disorders * drug therapy metabolism MeSH
- Receptors, Kainic Acid * antagonists & inhibitors MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Substance addiction is a complex mental disorder with significant unmet treatment needs, especially in terms of effective medications. Craving in addiction is closely linked to the interaction between dopamine and glutamate in the brain's reward pathway. Therefore, drugs targeting glutamatergic signaling may have potential for treatment. This review examines the potential of AMPA/kainate glutamatergic receptor antagonists in reducing addictive-like behaviours in experimental rodents. To this end, the text summarizes the behavioural results of preclinical studies on stimulant substances (cocaine, amphetamine, methamphetamine, MDMA), nicotine, opioids (morphine and heroin), and alcohol. These experiments employ various protocols and routes of administration, using different strains of mice and rats. The main behavioural methods used in the research include behavioural sensitization protocols, drug-induced locomotor activity assessments, conditioned behaviours, and operant self-administration models. The reviewed literature demonstrates the benefit of AMPA/kainate antagonists, mainly in the most studied cocaine dependence, and particularly in attenuating cocaine-seeking behaviour via microinjection into the nucleus accumbens core. Regarding other addictive substances, despite some conflicting results, there is a substantial body of literature showing promising outcomes following systemic or intracerebral administration of AMPA/kainate antagonists. The main issue is the variability of the research protocols used across laboratories, including differences in animal species, strains, sex and environmental conditions. Moreover, each addictive substance exhibits distinct mechanisms of action and addiction development, rendering the pursuit of a universal drug for addiction treatment unrealistic. Nevertheless, AMPA/kainate antagonists seem to have potential as a supportive treatment in addiction to cocaine as well as other substances.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016185
- 003
- CZ-PrNML
- 005
- 20250731091600.0
- 007
- ta
- 008
- 250708e20250403enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pnpbp.2025.111355 $2 doi
- 035 __
- $a (PubMed)40187601
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hrickova, Maria $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 245 10
- $a Do AMPA/kainate antagonists possess potential in the treatment of addiction? Evidence from animal behavioural studies / $c M. Hrickova, J. Ruda-Kucerova
- 520 9_
- $a Substance addiction is a complex mental disorder with significant unmet treatment needs, especially in terms of effective medications. Craving in addiction is closely linked to the interaction between dopamine and glutamate in the brain's reward pathway. Therefore, drugs targeting glutamatergic signaling may have potential for treatment. This review examines the potential of AMPA/kainate glutamatergic receptor antagonists in reducing addictive-like behaviours in experimental rodents. To this end, the text summarizes the behavioural results of preclinical studies on stimulant substances (cocaine, amphetamine, methamphetamine, MDMA), nicotine, opioids (morphine and heroin), and alcohol. These experiments employ various protocols and routes of administration, using different strains of mice and rats. The main behavioural methods used in the research include behavioural sensitization protocols, drug-induced locomotor activity assessments, conditioned behaviours, and operant self-administration models. The reviewed literature demonstrates the benefit of AMPA/kainate antagonists, mainly in the most studied cocaine dependence, and particularly in attenuating cocaine-seeking behaviour via microinjection into the nucleus accumbens core. Regarding other addictive substances, despite some conflicting results, there is a substantial body of literature showing promising outcomes following systemic or intracerebral administration of AMPA/kainate antagonists. The main issue is the variability of the research protocols used across laboratories, including differences in animal species, strains, sex and environmental conditions. Moreover, each addictive substance exhibits distinct mechanisms of action and addiction development, rendering the pursuit of a universal drug for addiction treatment unrealistic. Nevertheless, AMPA/kainate antagonists seem to have potential as a supportive treatment in addiction to cocaine as well as other substances.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a AMPA receptory $x antagonisté a inhibitory $7 D018091
- 650 12
- $a poruchy spojené s užíváním psychoaktivních látek $x farmakoterapie $x metabolismus $7 D019966
- 650 12
- $a receptory kyseliny kainové $x antagonisté a inhibitory $7 D018092
- 650 12
- $a antagonisté excitačních aminokyselin $x terapeutické užití $x farmakologie $7 D018691
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a návykové chování $x farmakoterapie $7 D016739
- 650 12
- $a chování zvířat $x účinky léků $7 D001522
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: jkucer@med.muni.cz
- 773 0_
- $w MED00003930 $t Progress in neuro-psychopharmacology & biological psychiatry $x 1878-4216 $g Roč. 138 (20250403), s. 111355
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40187601 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091555 $b ABA008
- 999 __
- $a ok $b bmc $g 2366785 $s 1253310
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 138 $c - $d 111355 $e 20250403 $i 1878-4216 $m Progress in neuro-psychopharmacology & biological psychiatry $n Prog Neuropsychopharmacol Biol Psychiatry $x MED00003930
- LZP __
- $a Pubmed-20250708